UKIMWI kwisha habari yake!

[zipompa]

Imenibidi kuzama google kwanza nione hii Gammora drug. nkakuta ugunduzi umetangazwa kama siku 6 nyuma ivi

shida hii kitu kufika kwetu tunaweza kuwa tusha kata moto maana gharama yake ni kubwa mno

 

[Trouton]

Bado wapo kwenye trial, sasa wewe kajiachie na michepuko yako uunase. Amin amin nakwambia, utaisubiri dawa kama mwizi anayepokea kichapo cha raia anavyoisubiria defender ya polisi imuokoe.

 

[dalaber]

Huu uvumbuzi ni wa muda mrefu wazungu wanabania tu

 

[yello masai]

Sijaelewa

 

[Retired]

By ANGELA OKETCH
Results of the first human clinical trial of the HIV drug, Gammora, have shown that it can eliminate up to 99 per cent of the virus within four weeks of treatment.
The results released Sunday show that Gammora significantly reduced the viral load in human subjects by killing infected cells without harming healthy ones, unlike antiretroviral drugs which suppress the spreading of the virus.

APOPTOSIS
The study was done by researchers from Zion Medical, an Israeli biotech company, and the Hebrew University of Jerusalem.
“The drug triggers the self-destruction of the infected cell called apoptosis. It has the potential to cure HIV-infected patients by destroying all cells carrying the HIV genome.

RANDOMLY
“These first clinical results were beyond our expectations and promise hope in finding a cure for the disease,” Dr Esmira Naftali, head of development at Zion Medical, said, adding that nine patients at Ronald Bata Memorial Hospital in Uganda were randomly assigned to receive different doses of the drug for four to five weeks.
In the second part of the trial done two weeks later, patients were given the drug with additional retroviral treatment after four to five weeks.

VIRAL LOAD
Patients received either lopinavir 800 mg and ritonavir 200 mg (LPV+r) daily in combination with Gammora administered twice a week, or LPV+r only.
The results showed that the combined treatments eliminated up to 99 per cent of the viral load within four weeks without exhibiting any side effects.
During the 10-week study, patients in both groups showed a significant increase in T-cell count — another name for CD4 cells, which play a role in the body’s immune system.

DOSAGE
“Given the limited nature of this study, we are excited to prove the efficiency of our drug in phase 2b with a greater number of participants over a longer period of time,” Dr Naftali said.
Prof Abraham Loyter of the Hebrew University of Jerusalem started the study a decade ago. Phase Two is expected to begin in the coming months, expanding the pool of subjects to 50 and the dosage period to three months.

ENZYME
The drug is derived from HIV enzyme integrate that is responsible for inserting the virus’s genetic material into the DNA of the infected cell.
There are indications that 1,493,382 Kenyans live with the virus, with the overall prevalence rate dropping to 4.8 per cent.

PROPHYLAXIS
The prevalence among women is 5.2 per cent and 4.5 per cent in men. More than 53,291 Kenyans are receiving pre-exposure prophylaxis.
The government intends to raise the number to half a million people by 2022.

Malaria has quite effective drugs but still is one of the leading cause of deaths and hospital admissions!

 

[Ileje]

Imenibidi kuzama google kwanza nione hii Gammora drug. nkakuta ugunduzi umetangazwa kama siku 6 nyuma ivi

shida hii kitu kufika kwetu tunaweza kuwa tusha kata moto maana gharama yake ni kubwa mno

Usijali WHO watasaidia kupunguza gharama kwani hata wazungu ni waathirika!

 

[Ileje]

Sijaelewa

Kula vitu kavu kavu dawa ipo!!

 

[uungwana classic]

Ambao wamesoma tu kichwa cha uzi na kuruka hadi kwenye comment gonga like mwanawani... rais kasema tuwe wazalendo tunamuunga mkono.

Kama vile umeniona yaani

 

[Black hermit]

Unakuta mtu hata marekani hajafika halafu anaandika kizungu hapa

 

[Sky Eclat]

Wazinzi watafanya karamu usiku kucha

Njia ile ni nyembamba iyendayo uzimani

 

[Mak Jr]

hamna lolote apo, ni yale yale ya kikombe cha babu Loliondo!

 

[Abuu Dharr]

By ANGELA OKETCH
Results of the first human clinical trial of the HIV drug, Gammora, have shown that it can eliminate up to 99 per cent of the virus within four weeks of treatment.
The results released Sunday show that Gammora significantly reduced the viral load in human subjects by killing infected cells without harming healthy ones, unlike antiretroviral drugs which suppress the spreading of the virus.

APOPTOSIS
The study was done by researchers from Zion Medical, an Israeli biotech company, and the Hebrew University of Jerusalem.
“The drug triggers the self-destruction of the infected cell called apoptosis. It has the potential to cure HIV-infected patients by destroying all cells carrying the HIV genome.

RANDOMLY
“These first clinical results were beyond our expectations and promise hope in finding a cure for the disease,” Dr Esmira Naftali, head of development at Zion Medical, said, adding that nine patients at Ronald Bata Memorial Hospital in Uganda were randomly assigned to receive different doses of the drug for four to five weeks.
In the second part of the trial done two weeks later, patients were given the drug with additional retroviral treatment after four to five weeks.

VIRAL LOAD
Patients received either lopinavir 800 mg and ritonavir 200 mg (LPV+r) daily in combination with Gammora administered twice a week, or LPV+r only.
The results showed that the combined treatments eliminated up to 99 per cent of the viral load within four weeks without exhibiting any side effects.
During the 10-week study, patients in both groups showed a significant increase in T-cell count — another name for CD4 cells, which play a role in the body’s immune system.

DOSAGE
“Given the limited nature of this study, we are excited to prove the efficiency of our drug in phase 2b with a greater number of participants over a longer period of time,” Dr Naftali said.
Prof Abraham Loyter of the Hebrew University of Jerusalem started the study a decade ago. Phase Two is expected to begin in the coming months, expanding the pool of subjects to 50 and the dosage period to three months.

ENZYME
The drug is derived from HIV enzyme integrate that is responsible for inserting the virus’s genetic material into the DNA of the infected cell.
There are indications that 1,493,382 Kenyans live with the virus, with the overall prevalence rate dropping to 4.8 per cent.

PROPHYLAXIS
The prevalence among women is 5.2 per cent and 4.5 per cent in men. More than 53,291 Kenyans are receiving pre-exposure prophylaxis.
The government intends to raise the number to half a million people by 2022.

Watengeneze Virus wao

Kisha baada ya kuuwa watu wapuuzi hawa
wanatuletea dawa eti

kisha kuna viatu
Vinawasapoti wauwaji hawa na waharibifu

 

[NIYOMBARE]

Hii habari itafanya watu waanze zinaa rasmi. Ila biashara nyingi zitasimama. biashara ya kondomu, biashara ya matangazo na semina za malipo kuhusu utoaji elimu kuhusu maambukizi ya UKIMWI. Biashara ya ARVs.

Utaibuka mwingine wakuziba pengo

 

[Scars]

Leo ni siku yangu ya kupita pale sinza na kuopoa chombo kimoja matata nikapige kavu kavu

Kapige kavu mkuu ila usifikili dawa watakuuzia kwa bei ya jackpot kama ARV

 

[squirtinator]

Dawa haitapatikana kama tutaendelea kumtegemea mzungu. Hawezi wapa dawa wakati ni mtaji kwake kuwauzia arv.

 

[Abuu Dharr]

Hii dawa ikatangazwe kwenye misikiti yote na waumini wote waseme kwenye vipaza sauti vyao “Hakika Umebarikiwa Ee Jerusalemu”

Watu wa ajabu sana!!!!

Dahhh

 

[Ulweso]

Huu uvumbuzi ni wa muda mrefu wazungu wanabania tu

Wenyewe sio waathirika wakubwa ndiyo maana hivyo, huku sie kwenye bara giza tunajiachia kupita maelezo

 

[squirtinator]

Kwa wale wanatafuta wake, mwanamke wa kuoa ni yule aliyepona ukimwi(kama kweli dawa ipo). Huyo atakuwa anajua kutulia maana atakuwa amepitia somo moja kali sana la maisha.

 

[zandrano]

UKIMWI HAUNA DAWA WALA KINGA. CHUKUA TAHADHARI. acha ngono

 

[Abuu Dharr]

Wapuuzi hao wasiokuwa na Huruma

Hulifanya hili Bara la Giza,kuwa ni sehemu yao ya mazoezi na utajirishi

Wameligeuza ni sawa na Dampo

Puuuzi kabsa